Advertisement

Topics

Dynavax Announces FDA Approval of HEPLISAV-B for Prevention of Hepatitis B in Adults / First and Only Two-Dose Vaccine in United States for Prevention of Hepatitis B in Adults First New Hepatitis B Vaccine in United States in More than 25 Ye

16:46 EST 9 Nov 2017 | FinanzNachrichten

BERKELEY, CA--(Marketwired - November 09, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatiti...

Original Article: Dynavax Announces FDA Approval of HEPLISAV-B for Prevention of Hepatitis B in Adults / First and Only Two-Dose Vaccine in United States for Prevention of Hepatitis B in Adults First New Hepatitis B Vaccine in United States in More than 25 Ye

NEXT ARTICLE

More From BioPortfolio on "Dynavax Announces FDA Approval of HEPLISAV-B for Prevention of Hepatitis B in Adults / First and Only Two-Dose Vaccine in United States for Prevention of Hepatitis B in Adults First New Hepatitis B Vaccine in United States in More than 25 Ye"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...